- Tel: 858.663.9055
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
BRAF V600E Antibody [clone V600E/1321] (V5229)
Email: info@nsjbio.com
| Catalog No | Formulation | Size | Price (USD) | ||
|---|---|---|---|---|---|
 |
V5229-100UG | 0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide | 100 ug | 519 | |
|
|
V5229-20UG | 0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide | 20 ug | 229 | |
|
|
V5229SAF-100UG | 1 mg/ml in 1X PBS; BSA free, sodium azide free | 100 ug | 519 |
|
| Availability | 1-3 business days |
| Species Reactivity | Human |
| Format | Purified |
| Clonality | Monoclonal (mouse origin) |
| Isotype | Mouse IgG1, kappa |
| Clone Name | V600E/1321 |
| Purity | Protein A/G affinity |
| UniProt | P15056 |
| Localization | Cytoplasm |
| Applications | ELISA (Order BSA-free format for coating) : |
| Limitations | This BRAF V600E antibody is available for research use only. |
|
Review this product on BioCompare and get a $20 Amazon gift card
|
Related Products
|
The BRAF gene encodes a cytoplasmic serine-threonine kinase, which initiates the activation of the mitogen-activated protein kinase (MAPK) signalling pathway. The oncogenic mutations in the kinase region of BRAF gene result in constitutive activation of the MAPK signalling pathway, leading to increased cell proliferation, resistance to apoptosis and tumor progression. The most common of all activating BRAF mutations leads to a substitution of valine (V) to glutamic acid (E) at the position 600 of the amino acid sequence. The BRAF V600E mutation is an important predictive and prognostic biomarker. The BRAF V600E mutation is detected in approximately 8% of all solid tumours, including 45% of papillary thyroid carcinomas, 40-60% of melanomas, 5-15% of colorectal adenocarcinomas, 35% of serous low grade and borderline ovarian carcinomas, 1-3% of non-small cell lung cancers, and 5-7% of cholangiocarcinomas. Furthermore, the BRAF V600E mutation is found in 100% of hairy cell leukaemia, 54% Erdheim-Chester disease, 38% of Langerhans cell histocytoses and 60% of pleomorphic xanthoastrocytomas.
Optimal dilution of the BRAF V600E antibody should be determined by the researcher.
An N-terminal KLH-conjugated peptide (amino acids 596-606, Cys-GLAT(E)KSRWSG) was used as the immunogen for the BRAF V600E antibody.
Aliquot the BRAF V600E antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.
Powered by Bioz
